Recent

% | $
Quotes you view appear here for quick access.

công ty Magal Security Systems Message Board

hshinti 14 posts  |  Last Activity: Jul 2, 2015 9:13 AM Member since: Jan 25, 2010
  • Juno is the better deal. Shows Juno has much more convincing evidence and potential.

    Sentiment: Strong Buy

  • Fred Hutch president says they’ve got cancer ‘running scared,’ predicts cure in 10 years
    BY JOHN COOK on June 30, 2015 at 10:42 am
    2 Comments Share 4.6k Tweet 130 Share 19 Reddit Pin
    Fred Hutchinson Cancer Research Center president Dr. Gary Gilliland speaks at the Life Science Innovation Northwest conference in Seattle.
    Fred Hutchinson Cancer Research Center president Dr. Gary Gilliland speaks at the Life Science Innovation Northwest conference in Seattle.
    There’s a tsunami on the horizon, and it has cancer “running scared.”

    Those were the words from Fred Hutchinson Cancer Research president Dr. Gary Gilliland, who spoke Tuesday at the WBBA’s Life Science Innovation Northwest conference in Seattle.

    “It is actually plausible that in 10 years we will have cures and therapies for most, if not all, human cancers,” said Gilliland. “And I am excited about that.”

    Dr. Gary Gilliland
    Dr. Gary Gilliland
    Gilliland painted an optimistic picture for the potential of curing cancer, pointing directly to the research from the Fred Hutch in the field of immuno-oncology — the idea of genetically training immune cells to “seek and destroy cancer.”

    That’s the promise of Juno Therapeutics, a Fred Hutch spin-out which on Monday announced a whopping $1 billion investment from Celgene to accelerate its novel cancer research approach.

    Gilliland, who joined the Fred Hutch last November, said that Juno’s approach for harnessing the immune system to fight cancer is truly groundbreaking. The technology is highly individualized, since it takes T-cells from a patient’s body and then re-engineers them to kill select cancer cells.

    “I have never seen anything like this in my life,” said Gilliland. “You would not believe the types of responses that you see. People who have … widespread disease that has been refractory for every treatment that we have — in some cases on death’s door — and you give this cell-based therapy that was developed by Stan Riddell and Phil Greenberg at the Hutch and these tumors just melt away. People go into continuous, complete remission. You don’t need to keep giving the drug. You give it once. One infusion. And that’s it.”

    These tumors just melt away. People go into continuous, complete remission. You don’t need to keep giving the drug. You give it once. One infusion. And that’s it.
    With ideas like those flowing from the Fred Hutch and other cancer research institutions, Gilliland says there’s a real “urgency” to make the technologies a reality. And he thinks Seattle is uniquely positioned to be the “epicenter” of these cutting-edge breakthroughs in immuno-oncology.

    “This is where it all started — that first Stem-cell transplant that helped inform us around the idea of the immune system to fight cancer,” he said.

    Asked by WBBA president Chris Rivera whether the Fred Hutch might have any other Junos brewing in its lab, Gilliland coyly said to “stay tuned.”

    “Yes, we do have some other opportunities that we are very excited about,” said Gilliland, noting that they’re looking work with the biotech industry to develop the approaches. “And it doesn’t just have to do with immuno-oncology. It has to do with some other strategies around stem-cell transplantation, for example, and others. But, stay tuned, and we will keep you posted.”

    Chris Rivera of the WBBA interviews Dr. Gary Gilliland of the Fred Hutch
    Chris Rivera of the WBBA interviews Dr. Gary Gilliland of the Fred Hutch
    Juno’s technologies have yet to make it to market, though the $1 billion investment by Celgene certainly will help speed up development. Even so, Gilliland noted that funding for organizations such as the Fred Hutch is a challenge given state and federal budget cuts. For example, Washington state’s Life Sciences Discovery Fund is in jeopardy of seeing its budget slashed, and the National Institutes of Health is shrinking.

    That comes even as the state of Oregon committed $200 million to the Oregon Health and Science University, helping the organization reach its $1 billion goal for cancer research funding.

    Gilliland called that a “spectacular” achievement, and said he looks at the deal with “envy” given the state of Oregon’s involvement.

    Gilliland also discussed the opportunity to tap the amazing amount of data being produced in drug research, using analytics and cloud-based systems to better track and analyze the data so that individual patients get the very best treatment. He said that type of “precision” medicine generates massive amounts of data.

    “The soaring costs of oncology care are simply not sustainable, and one way we can help address that is when we give a medicine to a person that has cancer, we know it is going to work for them, and that we don’t give medicines that are not going to work for them. But the data that that generates is almost incomprehensible, and when you think about that, you think: where better in the world would you want to be than in a city and a state that has Amazon and Microsoft? We are right in their backyard, or as I like to say, they are in our backyard. But we have an opportunity to more effectively integrate with them to understand how to manage big data, and how do we move up into the cloud. How do we understand how to integrate in order to leverage the abilities we have in our economy to bring both biotech and tech together in a way that is synergistic.”

    Sentiment: Strong Buy

  • Reply to

    JP Morgan analyst weighs in on JUNO

    by hshinti Jul 1, 2015 8:31 AM
    hshinti hshinti Jul 1, 2015 8:35 AM Flag

    The short thesis against JUNO is absurd. JUNO is going to be cash rich, share CELG's resources to expedite development of every aspect of future therapies and has them for 10 years. It's the Babe Ruth of Biopharma mentoring a young Ken Griffey Jr.

    Sentiment: Strong Buy

  • Although the partnership seems to be a win for both biotechnology companies, Cory Kasimov of J.P. Morgan was more bullish on Juno than Celgene. The analyst reiterated an Overweight rating on Juno and raised his price target from $66 to $83. Kasimov explains, “From JUNO’s perspective, this is clearly a big win; the deal provides a huge infusion of cash as well as validation for the company’s diversified approach within CAR-T, not to mention the overall potential of this nascent field.” Overall, the analyst believes the partnership will make Juno a more competitive player in the biotechnology field thanks to its new advanced capabilities.

    Sentiment: Strong Buy

  • May be quite fun today.

    Sentiment: Strong Buy

  • hshinti hshinti Jul 1, 2015 8:00 AM Flag

    Cover your shorts and you will feel much better. Then get a glass of wine and relax by the pool.

    Sentiment: Strong Buy

  • Heard on the Street

    By
    Charley Grant

    July 1, 2015

    0 COMMENTS

    With its new investment in Juno Therapeutics, Celgene is swinging for the fences. It is a good thing for shareholders, then, that Celgene can afford to strike out.

    Celgene is paying dearly to invest in Juno’s so-called CAR T-cell therapy, which aims to engineer the body’s own T cells to recognize and attack cancer cells. The deal calls for Celgene to pay $150 million for certain marketing and other rights while purchasing $846 million in newly issued stock at $93 a share, or roughly double Monday’s closing price. It also allows Celgene to buy additional shares at certain clinical milestones, for up to a 30% stake in Juno.

    In short, Celgene is investing about $1 billion in a company formed less than two years ago and that doesn’t yet generate revenue let alone profit. Needless to say, that is a significant gamble.

    Juno’s early-stage clinical data to treat certain forms of cancer has generated excitement among scientists and investors alike. But it doesn’t expect any of its treatment candidates to receive approval from the Food and Drug Administration before 2020.

    Meanwhile, others such as Novartis AG and the upstart Kite Pharma are racing to develop competing treatments. Yet any clarity on the economic value of CAR T treatments is years away. Until then, Celgene may not see any return on its investment.

    Celgene can afford to be patient, though. About two-thirds of its revenue comes from Revlimid, which treats blood cancer. While Celgene faces various legal challenges to its patents from generic drug makers and hedge-fund manager Kyle Bass , Revlimid isn’t slated to lose marketing exclusivity in the U.S. until 2027.

    Meanwhile, thanks to Revlimid, Celgene can pay the bills. Net income over the past four quarters was $2.4 billion, according to FactSet, and Celgene has more than $7 billion of cash on hand.

    Its strong financial position should limit the downside if the Juno investment falls flat. And should the company revolutionize cancer treatment, as some hopefully predict, Celgene shareholders will be taking a home-run trot.

    —Charley Grant

    Sentiment: Strong Buy

  • Buy the dips. This is a steal. Some would have you believe that CELG can't evaluate science. A total farce by the shorts. This is going back to 60's soon.

    Sentiment: Strong Buy

  • hshinti hshinti Jun 29, 2015 11:38 PM Flag

    "Just another way of giving the company money"...what a dummy lol.

  • Reply to

    You can report pjnj_happy for Posting Fraud

    by fku_holly May 17, 2015 11:54 PM
    hshinti hshinti May 18, 2015 9:45 AM Flag

    The SEC is going to have a field day with him and with you too.

  • Reply to

    Should Add: Just My Humble Opinion

    by pjnj_happy May 17, 2015 10:40 PM
    hshinti hshinti May 18, 2015 6:39 AM Flag

    Too late clown.

  • Reply to

    P3 Announcement Results Delay

    by pjnj_happy May 17, 2015 3:28 PM
    hshinti hshinti May 17, 2015 10:32 PM Flag

    You might be right. I sent your post to ICPT IR so they can monitor if you have inside info. Pity.

  • hshinti hshinti May 11, 2015 12:35 PM Flag

    Thank goodness you are anonymous dummy lol.

MAGS
4.29-0.12(-2.72%)Jul 7 4:00 PMEDT